Skip to main content Accessibility help
×
×
Home

Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study

  • Shinsuke Hidese (a1) (a2), Miho Ota (a1), Chisato Wakabayashi (a1), Takamasa Noda (a3), Hayato Ozawa (a4), Tsutomu Okubo (a4) and Hiroshi Kunugi (a1) (a2)...

Abstract

Objective

l-theanine, an amino acid uniquely contained in green tea (Camellia sinensis), has been suggested to have various psychotropic effects. This study aimed to examine whether l-theanine is effective for patients with major depressive disorder (MDD) in an open-label clinical trial.

Methods

Subjects were 20 patients with MDD (four males; mean age: 41.0±14.1 years, 16 females; 42.9±12.0 years). l-theanine (250 mg/day) was added to the current medication of each participant for 8 weeks. Symptoms and cognitive functions were assessed at baseline, 4, and 8 weeks after l-theanine administration by the 21-item version of the Hamilton Depression Rating Scale (HAMD-21), State-Trait Anxiety Inventory (STAI), Pittsburgh Sleep Quality Index (PSQI), Stroop test, and Brief Assessment of Cognition in Schizophrenia (BACS).

Results

HAMD-21 score was reduced after l-theanine administration (p=0.007). This reduction was observed in unremitted patients (HAMD-21>7; p=0.004) at baseline. Anxiety-trait scores decreased after l-theanine administration (p=0.012) in the STAI test. PSQI scores also decreased after l-theanine administration (p=0.030) in the unremitted patients at baseline. Regarding cognitive functions, response latency (p=0.001) and error rate (p=0.036) decreased in the Stroop test, and verbal memory (p=0.005) and executive function (p=0.016) were enhanced in the BACS test after l-theanine administration.

Conclusion

Our study suggests that chronic (8-week) l-theanine administration is safe and has multiple beneficial effects on depressive symptoms, anxiety, sleep disturbance and cognitive impairments in patients with MDD. However, since this is an open-label study, placebo-controlled studies are required to consolidate the effects.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study
      Available formats
      ×

Copyright

Corresponding author

Dr. Hiroshi Kunugi, Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan. Tel: +81 42 346 1714; Fax: +81 42 346 2094; E-mail: hkunugi@ncnp.go.jp

References

Hide All
1. Kennedy, SH. Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues Clin Neurosci 2008;10:271277.
2. Rock, PL, Roiser, JP, Riedel, WJ, Blackwell, AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 2014;44:20292040.
3. Hamon, M & Blier, P. Monoamine neurocircuitry in depression and strategies for new treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013;45:5463.
4. Rush, AJ, Trivedi, MH, Wisniewski, SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:19051917.
5. Freeman, MP, Mischoulon, D, Tedeschini, E et al. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry 2010;71:682688.
6. Nahas, R, Sheikh, O. Complementary and alternative medicine for the treatment of major depressive disorder. Can Fam Physician 2011;57:659663.
7. Yokogoshi, H, Kobayashi, M, Mochizuki, M, Terashima, T. Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res 1998;23:667673.
8. Kakuda, T, Nozawa, A, Sugimoto, A, Niino, H. Inhibition by theanine of binding of [3H]AMPA, [3H]kainate, and [3H]MDL 105,519 to glutamate receptors. Biosci Biotechnol Biochem 2002;66:26832686.
9. Tamano, H, Fukura, K, Suzuki, M, Sakamoto, K, Yokogoshi, H, Takeda, A. Preventive effect of theanine intake on stress-induced impairments of hippocamapal long-term potentiation and recognition memory. Brain Res Bull 2013;95:16.
10. Tamano, H, Fukura, K, Suzuki, M, Sakamoto, K, Yokogoshi, H, Takeda, A. Advantageous effect of theanine intake on cognition. Nutr Neurosci 2014;17:279283.
11. Lardner, AL. Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders. Nutr Neurosci 2014;17:145155.
12. Unno, K, Fujitani, K, Takamori, N et al. Theanine intake improves the shortened lifespan, cognitive dysfunction and behavioural depression that are induced by chronic psychosocial stress in mice. Free Radic Res 2011;45:966974.
13. Wakabayashi, C, Numakawa, T, Ninomiya, M, Chiba, S, Kunugi, H. Behavioral and molecular evidence for psychotropic effects in L-theanine. Psychopharmacology 2012;219:10991109.
14. Wise, LE, Premaratne, ID, Gamage, TF et al. L-theanine attenuates abstinence signs in morphine-dependent rhesus monkeys and elicits anxiolytic-like activity in mice. Pharmacol Biochem Behav 2012;103:245252.
15. Tian, X, Sun, L, Gou, L et al. Protective effect of L-theanine on chronic restraint stress-induced cognitive impairments in mice. Brain Res 2013;1503:2432.
16. Kimura, K, Ozeki, M, Juneja, LR, Ohira, H. L-Theanine reduces psychological and physiological stress responses. Biol Psychol 2007;74:3945.
17. Nobre, AC, Rao, A, Owen, GN. L-theanine, a natural constituent in tea, and its effect on mental state. Asia Pac J Clin Nutr 2008;17(Suppl. 1):167168.
18. Gomez-Ramirez, M, Kelly, SP, Montesi, JL, Foxe, JJ. The effects of L-theanine on alpha-band oscillatory brain activity during a visuo-spatial attention task. Brain Topogr 2009;22:4451.
19. Gomez-Ramirez, M, Higgins, BA, Rycroft, JA et al. The deployment of intersensory selective attention: a high-density electrical mapping study of the effects of theanine. Clin Neuropharmacol 2007;30:2538.
20. Knyazev, GG. Motivation, emotion, and their inhibitory control mirrored in brain oscillations. Neurosci Biobehav Rev 2007;31:377395.
21. Foxe, JJ, Morie, KP, Laud, PJ, Rowson, MJ, de Bruin, EA, Kelly, SP. Assessing the effects of caffeine and theanine on the maintenance of vigilance during a sustained attention task. Neuropharmacology 2012;62:23202327.
22. Park, SK, Jung, IC, Lee, WK et al. A combination of green tea extract and L-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study. J Med Food 2011;14:334343.
23. Ritsner, MS, Miodownik, C, Ratner, Y et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry 2011;72:3442.
24. Ota, M, Wakabayashi, C, Sato, N et al. Effect of L-theanine on glutamatergic function in patients with schizophrenia. Acta Neuropsychiatr 2015;27:291296.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Arlington, VA: American Psychiatric Association, 2013.
26. Sheehan, DV, Lecrubier, Y, Sheehan, KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl. 20):2233.
27. Inada, T, Inagaki, A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci 2015;69:440447.
28. Williams, JB, Kobak, KA, Bech, P et al. The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol 2008;23:120129.
29. Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:5662.
30. Spielberg, CD. GRLaLRE. STAI Manual. Palo Alto, CA: Consulting Psychologists Press, 1970.
31. Buysse, DJ, Reynolds, CF 3rd, Monk, TH, Berman, SR, Kupfer, DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193213.
32. Lingjaerde, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgen, K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1100.
33. Stroop, JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643662.
34. Keefe, RS, Goldberg, TE, Harvey, PD, Gold, JM, Poe, MP, Coughenour, L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68:283297.
35. MacLeod, CM, MacDonald, PA. Interdimensional interference in the Stroop effect: uncovering the cognitive and neural anatomy of attention. Trends Cogn Sci 2000;4:383391.
36. Gardener, MC, Gillman, MP. Analyzing variability in nectar amino acids: composition is less variable than concentration. J Chem Ecol 2001;27:25452558.
37. Seretti, A, Cusin, C, Lattuada, E, Di Bella, D, Catalano, M, Smeraldi, E. Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Mol Psychiatry 1999;4:280283.
38. Riedel, M, Moller, HJ, Obermeier, M et al. Response and remission criteria in major depression – a validation of current practice. J Psychiatr Res 2010;44:10631068.
39. Skolnick, P, Popik, P, Trullas, R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009;30:563569.
40. Hashimoto, K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009;61:105123.
41. Newport, DJ, Carpenter, LL, McDonald, WM, Potash, JB, Tohen, M, Nemeroff, CB, Biomarkers APACoRTFoN, & Treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015;172:950966.
42. Caddy, C, Giaroli, G, White, TP, Shergill, SS, Tracy, DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 2014;4:7599.
43. Miller, OH, Moran, JT, Hall, BJ. Two cellular hypotheses explaining the initiation of ketamine’s antidepressant actions: direct inhibition and disinhibition. Neuropharmacology 2016;100:1726.
44. Bergink, V, van Megen, HJ, Westenberg, HG. Glutamate and anxiety. Eur Neuropsychopharmacol 2004;14:175183.
45. Yamada, T, Terashima, T, Okubo, T, Juneja, LR, Yokogoshi, H. Effects of theanine, r-glutamylethylamide, on neurotransmitter release and its relationship with glutamic acid neurotransmission. Nutr Neurosci 2005;8:219226.
46. Kimura, R, Murata, T. Influence of alkylamides of glutamic acid and related compounds on the central nervous system. I. Central depressant effect of theanine. Chem Pharm Bull 1971;19:12571261.
47. Lyon, MR, Kapoor, MP, Juneja, LR. The effects of L-theanine (Suntheanine(R)) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial. Altern Med Rev 2011;16:348354.
48. Dodd, FL, Kennedy, DO, Riby, LM, Haskell-Ramsay, CF. A double-blind, placebo-controlled study evaluating the effects of caffeine and L-theanine both alone and in combination on cerebral blood flow, cognition and mood. Psychopharmacology 2015;232:25632576.
49. Roberts, KL, Hall, DA. Examining a supramodal network for conflict processing: a systematic review and novel functional magnetic resonance imaging data for related visual and auditory stroop tasks. J Cogn Neurosci 2008;20:10631078.
50. Godsil, BP, Kiss, JP, Spedding, M, Jay, TM. The hippocampal-prefrontal pathway: the weak link in psychiatric disorders? Eur Neuropsychopharmacol 2013;23:11651181.
51. Marsden, WN. Synaptic plasticity in depression: molecular, cellular and functional correlates. Prog Neuropsychopharmacol Biol Psychiatry 2013;43:168184.
52. Zhang, G, Miura, Y, Yagasaki, K. Effects of dietary powdered green tea and theanine on tumor growth and endogenous hyperlipidemia in hepatoma-bearing rats. Biosci Biotechnol Biochem 2002;66:711716.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Acta Neuropsychiatrica
  • ISSN: 0924-2708
  • EISSN: 1601-5215
  • URL: /core/journals/acta-neuropsychiatrica
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed